ELVN
Enliven Therapeutics Inc.
$42.53
+$0.99(+2.38%)
51
Overall
60
Value
54
Tech
39
Quality
Market Cap
$1.12B
Volume
538.92K
52W Range
$14.79 - $48.53
Target Price
$56.78
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $41.7M | $51.4M | $38.8M | $83.5M | $104.6M | $119.7M | ||
| Research & Development | $32.2M | $38.4M | $31.0M | $64.6M | $80.8M | $85.9M | ||
| Research Expense | $32.2M | $38.4M | $31.0M | $64.6M | $80.8M | $85.9M | ||
| Selling, General & Administrative | $9.5M | $13.0M | $7.8M | $19.0M | $23.8M | $33.8M | ||
| General & Administrative Expenses | $9.5M | $13.0M | $7.8M | $19.0M | $23.8M | $33.8M | ||
| Salaries & Wages | -- | -- | -- | $12.9M | -- | -- | ||
| Depreciation & Amortization | $100.0K | $100.0K | $200.0K | $300.0K | $300.0K | -- | ||
| Depreciation & Amortization | $100.0K | $100.0K | $200.0K | $300.0K | -- | -- | ||
| Other Operating Expenses | $200.0K | $300.0K | $-110.0K | $-3.3M | $104.6M | $119.7M | ||
| OPERATING INCOME | ||||||||
| Operating income | $-41.7M | $-51.4M | $-38.8M | $-83.5M | $-104.6M | $-119.7M | ||
| EBITDA | $-41.1M | $-51.1M | $-37.4M | $-71.3M | $-103.4M | $-119.7M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $-14.9M | $-16.0M | ||
| Intinc | $483.0K | $233.0K | $1.1M | $12.0M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $483.0K | $233.0K | $-1.1M | $12.0M | $14.9M | $16.0M | ||
| Other Income/Expense | $145.0K | $175.0K | $-34.9M | $22.0K | $2.0K | $49.0K | ||
| Other Special Charges | $-145.0K | $-175.0K | $-97.0K | $-22.0K | $-2.0K | $-49.0K | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-41.4M | $-51.4M | $-37.7M | $-71.6M | $-103.7M | $-119.9M | ||
| Pre-Tax Income | $-41.4M | $-51.4M | $-37.7M | $-71.6M | $-89.7M | $-103.7M | ||
| INCOME TAX | ||||||||
| Tax Provision | -- | -- | $88.0K | -- | $232.0K | $-223.0K | ||
| NET INCOME | ||||||||
| Net Income | $-41.4M | $-51.4M | $-37.7M | $-71.6M | $-89.0M | $-103.7M | ||
| Net Income (Continuing Operations) | $-41.4M | $-51.4M | $-37.7M | $-71.6M | $-89.0M | $-103.7M | ||
| Net Income (Discontinued Operations) | $-41.4M | $-51.4M | $-37.7M | $-71.6M | $-89.0M | $-103.7M | ||
| Net Income (Common Stockholders) | $-49.2M | $-51.4M | $-37.7M | $-71.6M | $-89.0M | $-103.7M | ||
| Normalized Income | -- | $-40.6M | -- | -- | -- | $-103.9M | ||
| TOTALS | ||||||||
| Total Expenses | $41.7M | $51.4M | $38.8M | $83.5M | $104.6M | $119.7M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $3.5M | $5.4M | $6.6M | $35.5M | $47.1M | $56.7M | ||
| Average Shares Outstanding (Diluted) | $3.5M | -- | $6.6M | $35.5M | $47.1M | $56.7M | ||
| Shares Outstanding | $17.6M | $26.3M | $60.9M | $41.3M | $60.9M | $59.8M | ||
| Basic EPS | $-14.12 | $-9.48 | $0.24 | $-2.01 | $-1.89 | $-1.83 | ||
| Basic EPS (Continuing Operations) | $-14.12 | $-9.48 | $0.24 | $-2.01 | $-1.89 | $-1.83 | ||
| Diluted EPS | $-14.12 | $-9.48 | $0.24 | $-2.01 | $-1.89 | $-1.83 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $0.24 | $-2.01 | $-1.89 | $-1.83 | ||
| OTHER METRICS | ||||||||
| Accretion On Preferred Stock | $7.9M | $7.9M | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | $35.0M | -- | -- | -- | ||
| Other Gand A | $9.5M | $13.0M | $7.8M | $19.0M | $23.8M | $33.8M | ||
| Preferred Stock Dividends | $7.9M | $7.9M | -- | -- | -- | -- | ||
| Rent And Landing Fees | -- | -- | $200.0K | $300.0K | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELVN | $42.53 | +2.4% | 538.92K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enliven Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW